Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Sichuan Kelun Biotech Biopharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia overview
Gene-modified cell therapy is under development for the treatment of relapsed and refractory acute myeloid leukemia. The therapeutic candidate (CAR-NK) comprises NK cells genetically manipulated to express chimeric antigen receptor (CAR) targeting cells expressing CD33 antigen.
Sichuan Kelun Biotech Biopharmaceutical overview
Sichuan Kelun Biotech Biopharmaceutical (Sichuan Kelun) is engaged in focusing on registration, research and development, and global collaboration. The company is the subsidiary of Kelun Pharmaceutical.
For a complete picture of Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.